Startups
MGC Pharmaceuticals Limited (‘MGC’) (ASX: MXC) is a Bio-Pharma company with a “Nature to Medicine” strategy at the forefront of the emerging global phyto-medicines market. With operations in the European Union, United Kingdom, Australia & Latin America, MGC is leading the market in research, production and sales of its pharmaceutical products. MGC has developed an efficient production pipeline of phyto-medications, led by two products currently prescribed to patients, with further products in clinical development and testing. All of MGC’s products are produced under the strict rule of euGMP guidelines and MGC holds one of the few facilities to be approved for compounding phytocannabinoid based medications, globally.
Which has three clinical arms:
a. Neurology
b. Oncology
c. Autoimmune
MGC Pharma’s mission is to provide “Cost Effective, Standardized, Affordable Medicines”. This mission is cemented by MGC Pharma having established a full EU-GMP certified facility in Slovenia, being one of the few companies in the world who has manufactured standardized API of phyto-medicines, and to have formulated those into effective, consistent, compliant phyto- medicines.
MGC Pharma two flagship products, CannEpil™ and CogniCann™, which are in late stage of clinical development, and are the first in MGC Pharma’s pipeline, with further products such as, InCann (crohn’s disease and colitis), Tetrinol (anorexia and cachexia) and TopiCann (anti-inflammatory) following close behind.
Which has three clinical arms:
a. Neurology
b. Oncology
c. Autoimmune
MGC Pharma’s mission is to provide “Cost Effective, Standardized, Affordable Medicines”. This mission is cemented by MGC Pharma having established a full EU-GMP certified facility in Slovenia, being one of the few companies in the world who has manufactured standardized API of phyto-medicines, and to have formulated those into effective, consistent, compliant phyto- medicines.
MGC Pharma two flagship products, CannEpil™ and CogniCann™, which are in late stage of clinical development, and are the first in MGC Pharma’s pipeline, with further products such as, InCann (crohn’s disease and colitis), Tetrinol (anorexia and cachexia) and TopiCann (anti-inflammatory) following close behind.
Overview
Location
Australia, Western Australia, Perth
Employees
11-50
Phone
+61 8 6382 3390
Founded date
2015
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 12, 2020 | MGC PHARMACEUTICALS LIMITED MGC Pharmaceuticals : Prospectus | MGC PHARMACEUTICALS LTD ACN 116 800 269 PROSPECTUS For the offer of 50,000 Shares in the capital of the Company at an issue price of $0.02 per Share to raise $1,000 (before expenses) (Offer). This Prospectus has been prepared for the purpos... |
| Aug 31, 2019 | A mini-guide to cannabis in Asia | “This is a New Year’s gift from the National Legislative Assembly to the government and the Thai people,” said the Chairman of the country’s draft committee, Somchai Sawangkarn, as the Thai parliament voted to amend the Narcotic Act of 1979... |
Reviews 0
FAQ about MGC Pharmaceuticals Ltd.
When was MGC Pharmaceuticals Ltd. founded?
MGC Pharmaceuticals Ltd. was founded in 2015.
What has the press written about MGC Pharmaceuticals Ltd.?
Parsers VC has collected 3 articles mentioning MGC Pharmaceuticals Ltd., among them “MGC PHARMACEUTICALS LIMITED MGC Pharmaceuticals : Prospectus” (Aug 12, 2020) and “A mini-guide to cannabis in Asia” (Aug 31, 2019).
Is MGC Pharmaceuticals Ltd. still active?
Yes, MGC Pharmaceuticals Ltd. is active; its latest activity on Parsers VC dates from Apr 5, 2022.